Adlai Nortye Ltd. American Depositary Shares (ANL)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look for a durable moat, consistent earnings, and a margin of safety. Adlai Nortye fails most of those tests. It is a 109-employee clinical-stage biopharmaceutical company with no reported revenue growth or profit growth, and only 0 years of filed annual results, so the computed Lynch category is none. FairStock's Piotroski F-Score is just 2/9; FairStock's ROE is -20.23%, ROCE is -8.70%, and its P/E at the 2026-10-13 close of $11.76 is -17.81 on a stated EPS of $-0.66, for which no fiscal period is provided. Debt is modest with D/E of 0.12, and FairStock's Altman Z-Score is 13.44, but that does not prove earning power. The market cap is $841.3M, while the 52-week range is $0.88-$17.25—a speculator's tape, not a value investor's ledger. The FairStock Score of 20/100 reinforces the weak financial profile. The pipeline—RAS-targeting programs AN9025 and AN4035 and immunotherapy AN8025—could be valuable if trials succeed, but no approved product or recurring revenue is shown. Without profits, book value, or cash-flow data, valuation rests on future clinical events, not present value. Mr. Market can price hope richly, and this stock has swung from $0.88 to $17.25 in the past year. A value approach requires evidence of durable cash generation or a discount to real assets; neither is provided here. Biotechnology can create enormous value, but only after science, regulatory, and financing risks are cleared. Until then, I treat it as a speculation, not an investment.

In plain English: Adlai Nortye is a small company that develops cancer treatments. It is not yet profitable and has no reported sales growth, so the business looks weak on the numbers given. Because there are no profits or clear asset value in the data, the stock is hard to call cheap; it looks speculative and has been very volatile.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer